Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.
Also called NCT01618214
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 344 participants
- Sponsor
- Registry
-
NCT01618214
-
- Main results
- Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01618214. Randomized; no masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-05-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- biphasic insulin aspart 30
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01618214- Content hash
a331ccd30120e9757fdaf75b71a1a89b66ce22ce8a47b1268b74f44442a43410